𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Intranasal insulin: PK profile designed specifically for prandial treatment of Type 2 Diabetes

✍ Scribed by Richard L. Mitchell; Henry R. Costantino; Anthony Sileno; Timothy Duffy; Gordon Brandt; Steven C. Quay

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
138 KB
Volume
69
Category
Article
ISSN
0272-4391

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The effect of a new specificΞ±-amylase in
The effect of a new specificΞ±-amylase inhibitor on post-prandial glucose and insulin excursions in normal subjects and Type 2 (non-insulin-dependent) diabetic patients
✍ H. G. Eichler; A. Korn; S. Gasic; W. Pirson; J. Businger πŸ“‚ Article πŸ“… 1984 πŸ› Springer 🌐 English βš– 324 KB

Trestatin (Ro 9-0154), a new specific alpha-amylase inhibitor of microbial origin, was tested in six normal subjects and seven Type 2 (non-insulin-dependent) diabetic patients. In normal subjects the maximal increases in blood glucose following a 115-g starch meal were 2.19 +/- 0.57 mmol/l (mean +/-

Association of anAPOC3promoter variant w
Association of anAPOC3promoter variant with type 2 diabetes risk and need for insulin treatment in lean persons
✍ M. van Hoek; T. W. van Herpt; A. Dehghan; A. Hofman; A. G. Lieverse; C. M. van D πŸ“‚ Article πŸ“… 2011 πŸ› Springer 🌐 English βš– 153 KB

## Aims/hypothesis An __APOC3__ promoter haplotype has been previously associated with type 1 diabetes. In this population-based study, we investigated whether __APOC3__ polymorphisms increase type 2 diabetes risk and need for insulin treatment in lean participants. ## Methods In the Rotterdam St